Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia.
暂无分享,去创建一个
Shingo Matsumoto | James B. Mitchell | Murali C Krishna | Nallathamby Devasahayam | Sankaran Subramanian | Hironobu Yasui | C. Gadisetti | S. Matsumoto | M. Krishna | J. Munasinghe | Keita Saito | James B Mitchell | S. Subramanian | N. Devasahayam | Keita Saito | Chandramouli Gadisetti | Hironobu Yasui | Sonny Batra | Rajani Choudhuri | Jeeva P Munasinghe | S. Batra | R. Choudhuri
[1] M. Dewhirst,et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. , 1996, Cancer research.
[2] M. Dewhirst. Relationships between Cycling Hypoxia, HIF-1, Angiogenesis and Oxidative Stress , 2009, Radiation research.
[3] S M Evans,et al. Quantification of longitudinal tissue pO2 gradients in window chamber tumours: impact on tumour hypoxia , 1999, British Journal of Cancer.
[4] V. Grégoire,et al. Decrease in Tumor Cell Oxygen Consumption after Treatment with Vandetanib (ZACTIMA™; ZD6474) and its Effect on Response to Radiotherapy , 2009, Radiation research.
[5] Kevin Brindle,et al. New approaches for imaging tumour responses to treatment , 2008, Nature Reviews Cancer.
[6] Martyna Elas,et al. Electron paramagnetic resonance oxygen image hypoxic fraction plus radiation dose strongly correlates with tumor cure in FSa fibrosarcomas. , 2008, International journal of radiation oncology, biology, physics.
[7] V. Grégoire,et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] Benoit Macq,et al. Physiological noise in murine solid tumours using T2*-weighted gradient-echo imaging: a marker of tumour acute hypoxia? , 2004, Physics in medicine and biology.
[9] Rakesh K. Jain,et al. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.
[10] Division on Earth. Guide for the Care and Use of Laboratory Animals , 1996 .
[11] James B. Mitchell,et al. Low-field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice. , 2010, Cancer research.
[12] L. Akslen,et al. Role of Angiogenesis in Human Tumor Dormancy: Animal Models of the Angiogenic Switch , 2006, Cell cycle.
[13] D. Hallahan,et al. SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. , 2007, International journal of radiation oncology, biology, physics.
[14] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[15] James B. Mitchell,et al. Estimation of tumor microvessel density by MRI using a blood pool contrast agent. , 2009, International journal of oncology.
[16] Lei Xu,et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.
[17] V. Grégoire,et al. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. , 2006, Cancer research.
[18] Shingo Matsumoto,et al. Low-field paramagnetic resonance imaging of tumor oxygenation and glycolytic activity in mice. , 2008, The Journal of clinical investigation.
[19] J. Gallo,et al. Impact of Angiogenesis Inhibition by Sunitinib on Tumor Distribution of Temozolomide , 2008, Clinical Cancer Research.
[20] Mark W. Dewhirst,et al. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response , 2008, Nature Reviews Cancer.
[21] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[22] V. Grégoire,et al. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy. , 2006, Cancer research.
[23] Shingo Matsumoto,et al. Simultaneous imaging of tumor oxygenation and microvascular permeability using Overhauser enhanced MRI , 2009, Proceedings of the National Academy of Sciences.
[24] P. Wen,et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. , 2009, Cancer research.
[25] James H Thrall,et al. Imaging angiogenesis: applications and potential for drug development. , 2005, Journal of the National Cancer Institute.
[26] James B. Mitchell,et al. Imaging cycling tumor hypoxia. , 2010, Cancer research.
[27] Gabriele Bergers,et al. Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.
[28] A. Rowan. Guide for the Care and Use of Laboratory Animals , 1979 .
[29] M. Dewhirst,et al. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. , 2004, Cancer cell.
[30] R. Gillies,et al. Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.
[31] E. Smit,et al. Design of clinical trials of radiation combined with antiangiogenic therapy. , 2007, The oncologist.
[32] Arjun G. Yodh,et al. Epidermal Growth Factor Receptor Inhibition Modulates the Microenvironment by Vascular Normalization to Improve Chemotherapy and Radiotherapy Efficacy , 2009, PloS one.
[33] D. Chaplin,et al. Intermittent blood flow in a murine tumor: radiobiological effects. , 1987, Cancer research.
[34] R. Jain. A new target for tumor therapy. , 2009, The New England journal of medicine.
[35] Rakesh K Jain,et al. Molecular regulation of vessel maturation , 2003, Nature Medicine.